chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Diagnosis

Phases of Chronic Myeloid Leukemia

Chronic phase (CP)

  • Sometimes termed as chronic stable phase and the phase that is easily controlled with oral agents
  • Defined as <10% of blasts in the peripheral blood and bone marrow

Accelerated phase (AP)

  • Criteria for defining accelerated phase by the World Health Organization (WHO) (≥1 of the following):
    • 10-19% blasts in the peripheral blood smear or in the nucleated bone marrow cells
    • ≥20% basophils in the peripheral blood
    • Persistent thrombocytopenia (<100,000/µL platelets) that is unrelated to therapy
    • Persistent thrombocytosis (>1,000,000/µL platelets) that are unresponsive to therapy
    • Progressive splenomegaly and increased white cell count (>10 x 109/L) that is unresponsive to therapy
    • Cytogenetic evolution (chromosomal abnormalities other than Ph chromosome during therapy)
    • Hematologic resistance to 1st-line tyrosine kinase inhibitors (TKI) therapy
    • Hematologic, cytogenic, or molecular indications of resistance to 2 sequential tyrosine kinase inhibitors
    • ≥2 mutations in BCR-ABL1 during tyrosine kinase inhibitors therapy 
  • Modified criteria used at MD Anderson Cancer Center
    • ≥15% and 30% peripheral blood blasts
    • ≥30% combined peripheral blood blasts and promyelocytes
    • ≥20% peripheral blood basophils
    • ≤100 x 109/L platelet count unrelated to therapy
    • Clonal evolution in Ph+ cells

Blast phase (BP)

  • Disease progression may occur in patients without a preceding accelerated phase of chronic myeloid leukemia (AP-CML) and are refractory to treatment
  • Criteria for defining blast phase by the WHO
    • ≥20% blasts in the peripheral blood smear or bone marrow blasts
    • Presence of large foci or clusters of blasts in bone marrow biopsy
    • Presence of extramedullary blast infiltrates 
  • Criteria used by the International Bone Marrow Transplant Registry
    • ≥30% blasts in the blood, marrow, or both
    • Presence of extramedullary infiltrates of leukemic cells

Physical Examination

  • Complete history and physical examination including the size of the spleen

Laboratory Tests

  • Complete blood count (CBC) with differential and platelet count

Peripheral Blood Smear (PBS)

  • Absolute basophilia and eosinophilia as well as leukocytosis (approximately 100,000/µL)
  • Presence of mature metamyelocytes (“leukemic hiatus” or myelocyte bulge)
    • A classic finding in chronic myeloid leukemia

Bone Marrow Aspirate and Biopsy

  • Used as initial workup and for the detection of other chromosomal abnormalities that cannot be detected on peripheral blood fluorescence in situ hybridization (FISH)
  • Reveals a granulocytic hyperplasia with maturation pattern, increased reticulin fibrosis and vascularity, widened areas of immature neutrophils, decreased erythroid islands, presence of dwarf megakaryocytes, decreased iron-laden macrophages and increased cell turnover with pseudo-Gaucher cell and sea-blue histiocytes
  • Morphologic review contains percentage of the blast and basophils

Genetic Tests

  • Cytochemistry
    • Differentiates myeloid from lymphoid blasts in blastic phase of chronic myeloid leukemia
  • Cytogenetics
    • The test that initially discovered the Ph chromosome with the use of May-Grünwald-Giemsa (MGG) banded metaphase chromosomes
      • If Ph positive and BCR-ABL1 positive, a chronic or an advanced phase of chronic myeloid leukemia is confirmed
      • If Ph negative and BCR-ABL1 negative, the patient should be evaluated for other diseases than chronic myeloid leukemia
  • Fluorescence in situ hybridization (FISH) analysis
    • Used to detect the chromosomal position of the BCR and ABL1 genes in preparations containing metaphase chromosome
    • Also used in the utilization of the interphase cells in the bone marrow or peripheral blood
      • Presence of co-localization of the BCR and ABL probes indicates the presence of fused BCR-ABL1 genes
  • Quantitative reverse transcription-polymerase chain reaction (QPCR) using International Scale (IS)
    • Uses primers to amplify the DNA fragment from the mRNA transcripts of BCR-ABL1 genes
    • Can detect fusion of e1a2, e13a2 (b2a2), e14a2 (b3a2) and e19a2 genes
  • Other chromosomal abnormalities related to chronic myeloid leukemia (eg trisomy 8, trisomy 19, duplication of the Ph chromosome, isochromosome 17q)
    • Also known as additional clonal cytogenetic aberrations (ACAs)
    • Have poorer progression-free survival (PFS) and overall survival (OS)

Human Leukocyte Antigen (HLA) Testing

  • If the patient is considered for allogenic hematopoietic stem cell transplantation (HCT)

Assessment

Determination of Risk Score

Sokal Prognostic Score

  • Spleen size, percent blasts, age and platelet count >700,000/µL are used as variables
  • Low risk: <0.8
  • Intermediate risk: 0.8 - 1.2
  • High risk: >1.2

Hastford (EURO) Score

  • Developed for patients receiving Interferon therapy
  • Adds eosinophilia and basophilia to the other variables
  • Low risk: ≤780
  • Intermediate risk: >780 - ≤1480
  • High risk: >1480

European Treatment and Outcome Study (EUTOS) Long-term Survival (ELTS) Score

  • Scoring based on the percentage of basophils and size of the spleen
  • Additional studies may be needed to confirm importance of EUTOS in predicting clinical outcomes of patients receiving tyrosine kinase inhibitors therapy
  • Low risk: ≤1.5680
  • Intermediate risk: >1.5680 but ≤2.2185
  • High risk: >2.2185
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

3 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.